Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hawaii Pacific Health
• Collaborator: Genentech, Inc.
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Ability to provide informed consent and comply with study assessment for the duration of one year

• Age >= 25 years

• Polypoidal Choroidal Vasculopathy as noted on fluorescein and ICG angiography: active leakage, active bleeding or recent decrease in vision

• BCVA using ETDRS 20/32 to 20/400

Exclusion Criteria:

• Any history of previous vitrectomy

• Previous cataract or ocular surgery within 2 months of day 0

• Active intraocular inflammation in the study eye

• Active infections conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye

• Participation with another investigational drug within the past 30 days

• Prior sodium pegaptanib, verteporfin photodynamic therapy, intravitreal steroids, or bevacizumab within 30 days of study entry

• Blood pressure >180/110 (use of antihypertensives is allowed as long as hypertension can be controlled and is stable)

• Pregnancy